Monday, November 21, 2022

RADIATION THERAPY AND ITS EFFECT ON THE IMMUNE RESPONSE

RADIATION THERAPY AND ITS EFFECT ON THE IMMUNE RESPONSE





Just like chemotherapy and ablation, radiation kills tumors. Then, residues of the dead tumor tissue can act as antigens sent to the immune system. In general, radiation therapy can be considered immunosuppressive, but when it is combined with the immunotherapy process it creates a synergy.

Overall, Cryoablation is considered to be more effective than radiation in its ability to stimulate an immune response. However, it will be easier for most patients to choose a radiation procedure than cryoablation.

It is much easier to get health insurance coverage for a radiation procedure. Therefore, most patients go to this process, where it is also advisable to receive immunotherapy treatment.

Although there is evidence of the effectiveness of the applicability of this combination, finding a doctor who is willing to perform it is a complex process to achieve. Without a doubt, cryoablation should be the first choice, however, it is important to know the radiation characteristics.

One of the main functions of radiation is to cause the immune system to identify malignant cells and destroy them. Radiation can also activate the stimulator of interferon gene pathways (STING), which can stimulate a nonspecific innate immune response. On the other hand, this process can cause the release of FCT-B and VEGF, both are immunosuppressive. In addition, radiation can lower the white blood cell count, a condition that is associated with immune suppression.

There are many studies testing the combination of radiation with immunotherapy. There are still some issues to define: What is the appropriate dose to be administered in radiation therapy? How often should it be administered? Once the radiation process has begun, at what point is it recommended to perform immunotherapy? before, after or during the process? There are conflicting studies regarding these treatment details.

In some cases, patients have not had results with immunotherapy, but later when the radiation process was added, the immune response was activated.

So, there are some real potential benefits, and certainly patients who have not had good results with immunotherapy might want to consider adding radiation processes to help activate the immune response.

Some benefits could be derived from previous traditional cancer treatments such as chemotherapy and radiation associated with an anti-cancer immune response. There are currently numerous studies being carried out. The only factor to consider when it comes to chemotherapy is that most studies focus on the traditional method of administering the maximum tolerated dose. However, science has shown that it is more effective to administer a lower dose, but more frequently. Some doctors offer a low dose, metronomic chemotherapy, however, many of them are not oncologists, so it is advisable to seek appropriate advice.

Also, for a patient with cancer with large tumors, chemotherapy and radiation may be helpful in reducing the tumor burden, so that the immune system can fight it off.

More remains to be learned about when therapy should be administered. For example, studies in mice have shown that cyclophosphamide given before chemotherapy, doxorubicin for example, can stimulate an immune response against cancer, but the reverse suppresses the immune response. These types of findings can be variable depending on the type of cancer and its location, as well as the local immune environment of the tumor, which can significantly affect immune responses.

Although it is still being evaluated, this topic has been discussed at immunology meetings and conferences. There, it is discussed that if the maximum dose chemotherapy is applied first, it can reduce the success potential of the immunotherapy that is carried out later. This is probably related to suppression of the immune response.

References:

Williams, J. (2019, 15th October) The Immunotherapy Revolution. Pg 72-75



The post RADIATION THERAPY AND ITS EFFECT ON THE IMMUNE RESPONSE appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/radiation-therapy-and-its-effect-on-the-immune-response/?utm_source=rss&utm_medium=rss&utm_campaign=radiation-therapy-and-its-effect-on-the-immune-response

Tuesday, November 15, 2022

BLACK CUMIN SEED OIL POTENTIAL CO-ASSISTANT IN THE TREATMENT OF CANCER

BLACK CUMIN SEED OIL POTENTIAL CO-ASSISTANT IN THE TREATMENT OF CANCER





Black cumin seed oil is obtained from a small plant that comes from Southwest Asia, the Middle East, southern Europe, and North Africa. This plant produces tiny fruits from which oil is extracted and it has been used for more than 2,000 years due to its multiple benefits.

This plant is rich in antioxidants that are extremely important for health as they help protect cells against damage caused by unstable molecules called cell free radicals.

Moreover, antioxidants have been shown to help reduce inflammation and protect the body against illness such as heart disease, Alzheimer’s disease and cancer, as this oil is rich in thymoquinone, which has powerful antioxidant and anti-inflammatory effects.

Besides, this oil can protect brain health and help in the treatment of different types of cancer since it strengthens the immune system.

Black seeds and black cumin seed oil may reduce the side effects of chemotherapy treatments for different types of cancer, as they contain different active nutritional ingredients such as thymoquinone, which has been tested in patients and in laboratory studies. One of the main benefits of this seed is the reduction of fever and infections due to low neutrophil count in pediatric brain cancers, the reduction of toxicity side effect related to methotrexate (chemotherapy) in leukemia and a better response in patients with breast cancer treated with tamoxifen therapy.

Due to its high concentration of thymoquinone, omega 3 and carotenoids, cumin seeds could work as complementary foods that help us prevent cancer. These essential nutrients help protect cells against damage caused by oxidative stress and also help remove toxins. Therefore, they can also be useful to reduce the risk of suffering some cancers such as lung, kidney, prostate, liver, colon or skin.

When our body is attacked by cancer, it is important to start immunotherapy treatments and start adapting different lifestyles to improve our health. For example, regarding a new diet, it is advisable to supplement the diet with some natural products such as black cumin seed oil, which is an excellent helper in the fight against cancer because it is one of the natural supplements that has extensive preclinical data in cancer cell lines and animal models.

In the same way, it is advisable to consult with an immunotherapy specialist on issues related to the consumption of this product, since it is important to personalize nutrition for cancer treatments and specific treatment to obtain the benefits of nutrition.

References:

Cogle, C. R. (2022, 15th June). Aceite de semilla negra: aplicaciones en cánceres tratados con quimioterapia y efectos secundarios. addon.life. https://addon.life/es/2020/11/23/black-seed-chemo-side-effect/

 

McGrane, M. K. S. (2021, 27th September). Aceite de semilla negra: Beneficios, dosis y efectos secundarios. Healthline. https://www.healthline.com/health/es/aceite-de-semilla-negra



The post BLACK CUMIN SEED OIL POTENTIAL CO-ASSISTANT IN THE TREATMENT OF CANCER appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/black-cumin-seed-oil-potential-co-assistant-in-the-treatment-of-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=black-cumin-seed-oil-potential-co-assistant-in-the-treatment-of-cancer

Thursday, November 10, 2022

Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer

Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer





Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer
Galvanize Therapeutics aims to become the global leader in delivering medical technology innovations that drive biologic processes to treat a range of diseases, starting with treating chronic bronchitis symptoms, cardiac arrhythmias, and solid tumors. (PRNewsfoto/Galvanize Therapeutics)
NEWS PROVIDED BY
Galvanize Therapeutics, Inc.
Nov 10, 2022, 08:00 ET
INCITE ES clinical study results suggest the Aliya™ PEF system may stimulate an immune response

BOSTON, Nov. 10, 2022 /PRNewswire/ — Galvanize Therapeutics, Inc., a commercial-stage biomedical platform company operating at the convergence of engineering, biology and healthcare delivery, today announced promising clinical data using its Aliya™ Pulsed Electric Field (PEF) system in patients with non-small cell lung cancer (NSCLC).

Initial results from the INCITE-ES clinical study conducted outside of the U.S., presented at this week’s Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting, indicate that the Aliya PEF system has the potential to stimulate an immune response in NSCLC patients.

INCITE-ES is a prospective, two-arm, non-randomized, concurrently controlled, multi-center treat-and-resect study in patients with suspected or confirmed NSCLC stage IA2-IB. In 30 patients PEF energy was delivered to a solitary tumor either percutaneously or endoscopically at the time of biopsy, prior to surgical resection. Eight additional patients were enrolled in the non-treated control group. Data presented previously demonstrated safety and feasibility to deliver PEF with no device or procedure-related adverse events. In an initial cohort of 10 PEF treated patients, tertiary lymphoid structures (TLS) [average 43.1 ± 41.0, (range 5-113)] were observed within tumors post-PEF, whereas none were identified on pre-PEF biopsy. TLS accumulation was greater in the PEF treated group as compared to the non-treated control group. TLS formation, shown in other studies to generate anti-tumor immunity¹, is emerging as a strong prognostic and predictive biomarker2 associated with patient survival benefits in NSCLC3,4.

“The five-year survival rate for NSCLC has only modestly improved from 13% in the 1970s to 21.7% in 20195, despite advances in surgery, radiation and advanced therapeutics,” explained Marcelo Jimenez, MD, PhD, Professor of Surgery, Thoracic Surgery Department, Salamanca University Hospital, Spain, investigator in the INCITE ES clinical study. “New treatment approaches are critically needed in NSCLC, and early indications of the potential for pulsed- electric field energy to activate the patient’s immune system are very encouraging. I look forward to future studies assessing this novel immuno-oncology approach in more patients.”

“These early clinical data build upon the recent U.S. Food and Drug Administration (FDA) 510(k) clearance for the Aliya system for soft tissue ablation and add to our confidence that PEF has the potential to mutually kill target cells and create immunogenic molecules,” said Jonathan Waldstreicher, M.D., Founder and CEO of Galvanize Therapeutics. “We are eager to expand our clinical program to further understand the opportunity for PEF to stimulate the immune system to activate against NSCLC and other solid tumors.”

About Aliya™ PEF System
The Aliya PEF system delivers non-thermal, high-voltage, high-frequency electrical currents through a single monopolar electrode placed in the target tissue. The PEF energy destabilizes the cells, resulting in cell death.

The non-thermal modality of the Aliya PEF system preserves surrounding healthy tissue, enabling ablation near critical structures, such as nerves and blood vessels. The Aliya waveform and electrode are designed to maximize the potential for releasing tumor antigens and may stimulate an immune response, potentially disrupting the immunosuppressive tumor microenvironment.

The Aliya System is 510(k) cleared in the United States for the surgical ablation of soft tissue. It is not currently commercially available in any other geography.

About Galvanize Therapeutics™
Galvanize Therapeutics aims to become the global leader in delivering medical technology innovations that drive biologic processes to treat a range of diseases, starting with treating chronic bronchitis symptoms, cardiac arrhythmias, and solid tumors. Formed by ATP (Apple Tree Partners) in 2022, Galvanize is based in San Carlos, Calif., and is researching and commercializing its revolutionary Aliya Pulsed Electric Field (PEF) energy platform in the United States and Europe. For more information, please visit www.galvanizetx.com.

References:
1 Schumacher T N, Thommen D S. Tertiary lymphoid structures in cancer. Science. 2022; 375(6576):eabf9419.

2 Petitprez F, de Reynies A, Keung E. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556 – 560.

3 Sautès-Fridman C, Petitprez F, Calderaro J. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19:307 – 325.

4 Cottrell T R, Thompson E D, Forde P M. Pathologic features of response to neoadjuvant anti-PD-1 in resected non- small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853-1860.

5 American Lung Association, State of Lung Cancer 2019

SOURCE Galvanize Therapeutics, Inc.



The post Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/galvanize-therapeutics-presents-clinical-data-using-pulsed-electric-field-pef-energy-for-non-small-cell-lung-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=galvanize-therapeutics-presents-clinical-data-using-pulsed-electric-field-pef-energy-for-non-small-cell-lung-cancer

Chemotherapy and the Immune Response

Chemotherapy and the Immune Response





It is known that chemotherapy is the treatment against cancer that better debilitate the immune system since the drugs used during chemotherapy affect divided cells rapidly. Likewise, this process is carried out by many of the body’s cells that can be found in the blood, the mouth, the digestive tract, the nose, the nails, the vagina, and the hair.

Cancer cells are damaged by chemotherapy because they cannot be repaired alone. Healthy cells can usually repair damage from chemotherapy after treatment is finished. One exception is nerve cells in the hands and feet, which some chemotherapy drugs can permanently damage. As chemotherapy drugs damage the bone marrow, the marrow is less able to make red blood cells, white blood cells, and platelets. The most significant impact typically falls on the white blood cells. If the body does not have enough white blood cells, the body is more vulnerable to infection.

In general, chemotherapy has been recognized to depress the immune system. It is common to see a decrease in white blood cells with chemotherapy. However, even in this reduction in white blood cell count, chemotherapy can stimulate the immune system.

This situation could be contradictory; however, it is known that the immune system can attack tumors and protect them. So, if you can debilitate protective cells, in other words, regulatory cells that include Tregs and CSDMs, you can achieve a positive balance in the immune response against cancer.

What are some of the beneficial effects that chemotherapy can have? One of these effects is the death of immunogenic tumor cells through mechanisms that cause tumor antigens to be released and danger signals to be stimulated. Tumors killed by these methods can help enhance an immune response.

Furthermore, increasingly cancer produces many immuno-inhibitory substances, both by direct protein production and by-products of its metabolism. If cancer growth is directly suppressed by chemotherapy, it can be reduced, facilitating the work of the immune system. Similarly, specific chemotherapy agents may be associated with increased immune response.

According to those mentioned above, if a person is going to have chemotherapy treatment and there is the option of using different drugs, it is more beneficial to use medicines that positively affect the immune response. In addition, it is essential to take advantage of the potential synergy with immunotherapy.

Without a doubt, it is a complicated process since most oncologists disagree with this combination of therapies; low-dose chemotherapy, also called metronomic dosing, seems more effective when it comes to stimulating an immune response. Unfortunately, this is not the way oncologists usually administer chemotherapy.

Although chemotherapy may be wished to be a memory of the past, it may still have a use, especially in the current situation of immunotherapy. If the patient has advanced cancer with extensive tumors, they might need help using chemotherapy treatment to give them a little more control so the immune system has a chance to fight it off. Otherwise, a rapidly growing advanced cancer may outpace the immune system. Cancer usually has a significant advantage at the beginning, and chemotherapy can slow it down, allowing the immune system to catch up.

It is essential to understand that metronomic chemotherapy is much more recommended since it is low-dose and can achieve many of the objectives of slowing down cancer and boosting the immune response against cancer.

References:

Cómo la quimioterapia afecta el sistema inmunitario. (s. f.). https://www.breastcancer.org/es/organizar-la-vida/sistema-inmunitario/tratamientos-contra-el-cancer/quimioterapia

Williams, J. (2019, 15th October) The Immunotherapy Revolution. Pg 72-75



The post Chemotherapy and the Immune Response appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/chemotherapy-and-the-immune-response/?utm_source=rss&utm_medium=rss&utm_campaign=chemotherapy-and-the-immune-response

Wednesday, November 9, 2022

IL-34 a keyinhibitor of immunotherapy success

IL-34 a keyinhibitor of immunotherapy success




The post IL-34 a keyinhibitor of immunotherapy success appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/il-34-a-keyinhibitor-of-immunotherapy-success/?utm_source=rss&utm_medium=rss&utm_campaign=il-34-a-keyinhibitor-of-immunotherapy-success

Monday, November 7, 2022

Let’s talk ablation.

Let’s talk ablation.





The first thing we must define is the ablation term itself. According to the NCI (National Cancer Institute), ablation in the field of medicine is the process or procedure by which the removal or destruction of a part of the body or tissue or its function is achieved. Ablation can be done through surgery, hormonal therapies, the use of medications, radiofrequency, heat, freezing, or other methods. 1

Percutaneous ablation encompasses a set of techniques that destroy pathological tissue using needles inserted through the skin. Sometimes liquid agents will be used (such as absolute alcohol) and in other physical agents, which can transfer heat (radiofrequency and microwave thermoablation) or cold (cryoablation) to the tumor.

The procedure will always be performed using image guidance, with computerized axial tomography to have constant control and safety during the introduction of the needle and that the energy transfer is applied exclusively to the tumor. This minimally invasive technique will be performed under sedation or general anesthesia, depending on certain parameters.

How is it performed? It consists of placing one or several needles in the center of the tumor to be treated very precisely and guided by an imaging technique. Using different technologies, these needles apply energy that destroys a volume of tissue in a predictable and controlled manner, thus eliminating the tumor. Ablation can be curative in some cases and has a high level of scientific evidence. Among the best-known ablation technologies are radiofrequency, microwaves, or lasers (they destroy tissue at high temperatures); cryoablation or cryotherapy (destroys tissue by freezing) and irreversible electroporation PEF (Pulsed Electric Field that destroys tissue without using heat or cold, instead using very short but very intense electrical pulses).

The most common way to perform an ablation is percutaneous, that is, with a needle from the skin without opening the patient. Compared to conventional surgery, ablation causes fewer complications and has a shorter recovery time. If the tumor is difficult to access percutaneously, ablation can also be performed in the operating room where, with the organ exposed and guided by ultrasound, the needle will be placed in the tumor. The organs that can be treated with ablation are liver tumors, lung tumors, kidney tumors, pancreatic tumors, bone and soft tissue tumors, and recently thyroid tumors. Ablation is a treatment that often can be combined with immunotherapy, chemotherapy, or radiotherapy.

 

  1. https://www.cancer.gov


The post Let’s talk ablation. appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/lets-talk-ablation/?utm_source=rss&utm_medium=rss&utm_campaign=lets-talk-ablation

Wednesday, November 2, 2022

THE UROLITIN A CONTAINED IN THE POMEGRANATE CAN HELP IN THE FIGHT AGAINST COLORECTAL CANCER

THE UROLITIN A CONTAINED IN THE POMEGRANATE CAN HELP IN THE FIGHT AGAINST COLORECTAL CANCER





Cancer is an uncontrolled division of cells that have mutated and cause many problems in the body. In addition, these cancer cells have no control and spread throughout the body without any restriction, which is why they achieve to reproduce rapidly, causing metastasis.

Similarly, it is important to mention the metabolic endotoxemia, which causes several problems in the colon: the reproduction of cancer cells, for example. This is because cells known as intestinal bacteria dwell in the colon, which help in proper digestion in the body. There are cells that also help in the digestion of food that has not been digested by the body, this means that an unhealthy diet can cause the intestinal lining to leak, releasing metabolic endotoxins which act as inflammatory proteins that can lead to Colorectal cancer.

According to the aforementioned, studies supporting the fight against colorectal cancer have discovered a substance known as urolithin A, which is a product metabolite of pomegranate, which sustainably improves the function of immune cells in its fight against cancer.

Likewise, after research and treatment in colorectal cancer patients with urolithin A, more tumor-fighting immune cells have been detected, it has also been seen that this substance causes cytotoxic T cells to become stem cells with memory T that are supplied to the body with rejuvenated T cells and with energy.

Also, Treatment with urolithin A rejuvenates human T cells, also generates stem cells with memory T in the laboratory, all these findings have been found within the immune system, being the main defense against cancer.

Apart from this, pomegranate has been shown to have antiproliferative (prevents the reproduction of cancer cells) and pro-apoptosis (cell death caused by the same organism).

Unfortunately, people do not always react favorably to therapies due to the immune cells (T cells) are suppressed by the tissue surrounding the tumor, allowing the tumor to grow and spread, hence, this situation prevents these cells from accomplish their main function which is fighting cancerous tumors.

Urolithin A induces a biological that recycles and renews mitochondria, the cell’s “power plants” in T cells, through a process known as mitophagy. Aged and damaged mitochondria in T cells are removed and replaced with new, functional ones.

Additionally, Urolithin A limits tumor growth and even works simultaneously with existing immunotherapy. On the other hand, the benefits of urolithin A are also observed in human T cells since it produces a rejuvenation in them.

Without a doubt, foods rich in polyphenols such as pomegranate have the potential to reduce the levels of potentially harmful endotoxins in the blood that could help humans, especially those newly diagnosed with colorectal cancer and may help in the prevention or reduction of colorectal cancer.

Therefore, if you have been diagnosed with colorectal cancer, it would be very convenient to consume a greater amount of foods rich in polyphenols, such as pomegranates, blueberries, apples, vegetables, and red wine.

References:

Cogle, C. R. (2022, 15th July). ¿Puede el consumo de extracto de granada ayudar a reducir el riesgo de cáncer colorrectal? addon.life. https://addon.life/es/2021/07/31/c%C3%A1ncer-colorrectal-de-granada/

Staff, S. X. (2022, 20th October). Metabolite from pomegranates improves the function of immune cells in their fight against cancer. https://medicalxpress.com/news/2022-10-metabolite-pomegranates-function-immune-cells.html

 



The post THE UROLITIN A CONTAINED IN THE POMEGRANATE CAN HELP IN THE FIGHT AGAINST COLORECTAL CANCER appeared first on Williams Cancer Institute.



source https://williamscancerinstitute.com/the-urolitin-a-contained-in-the-pomegranate-can-help-in-the-fight-against-colorectal-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=the-urolitin-a-contained-in-the-pomegranate-can-help-in-the-fight-against-colorectal-cancer